image credit- shutterstock
Peptris Technologies, a Bengaluru-based AI-powered drug discovery startup, has entered into a licensing agreement with US-based Revio Therapeutics, a specialty pharma startup focused on repurposing and optimizing approved medicines.
Under the agreement, Peptris is licensing its preclinical-stage asset, PEPR124 (RT001) for an undisclosed amount to Revio Therapeutics for further development in Duchenne Muscular Dystrophy (DMD). The agreement is expected to accelerate Peptris’ AI-powered drug discovery efforts and expand its footprint in global biotech markets.
DMD is a rare genetic disorder primarily affecting boys, leading to progressive muscle degeneration, severe disability, and reduced life expectancy.With limited treatment options available, the global DMD market is valued at over $3 billion and represents a significant unmet need, driving demand for more effective and accessible therapies.
PEPR124 (RT001) was discovered by Peptris Technologies using its proprietary AI-driven drug discovery platform and has demonstrated promising efficacy in preclinical studies for DMD. It is a repurposed, mutation-agnostic, and safe therapeutic that could be a significant breakthrough therapeutic for not only DMD but other muscular dystrophies as well.
Under the terms of the agreement, Revio Therapeutics will hold commercialisation rights to PEPR124 (RT001) in all markets except in BRICS countries, which will be retained by Peptris.
